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ABSTRACT 
 
 
The human JC polyomavirus (JCPyV) persists as an asymptomatic infection in the 
kidneys of healthy individuals within the majority of the global population. Viral 
infection of JCPyV is established through peroral transmission due to poor sanitary 
practices. In severely immunocompromised individuals, JCPyV migrates to the central 
nervous system (CNS), resulting in the fatal and incurable demyelinating disease 
progressive multifocal leukoencephalopathy (PML). Virus-host cell interactions regulate 
infectious processes and influence viral pathogenesis. JCPyV attachment to host cells is 
mediated by α2,6-linked LSTc while internalization is mediated by 5-hydroxytryptamine 
serotonin type 2 receptors (5-HT2Rs). Activation of 5-HT2Rs can induce intracellular 
calcium (Ca2+) release upon ligand binding to activate the inositol triphosphate receptor 
(IP3R) signaling pathways. The goal of this project was to determine the role of 
intracellular Ca2+ flux in JCPyV infection. JCPyV induces Ca2+ flux from the ER almost 
immediately upon infection. Limiting Ca2+ release from the ER by inhibition of the IP3R 
with chemical antagonists significantly reduced JCPyV infection in both human kidney 
and brain cells, demonstrating a dependence on Ca2+ flux to regulate JCPyV infection. 
Although, JCPyV-induced Ca2+ flux occurs at times consistent with viral attachment and 
entry, analyses of these steps by flow cytometric assays, revealed that JCPyV attachment 
and entry were not affected by modulation of Ca2+ flux. These findings demonstrate that 
Ca2+ flux is regulated upon JCPyV infection and provide important insights into the 
activation of signaling pathways to drive the infectious process. In the future, this work 
can increase our understanding of PML pathogenesis and aid in the development of novel 
PML therapeutics.  
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1 
INTRODUCTION 
 
 
 
Overview 
Defined as obligate intracellular parasites, viruses are comprised of either an RNA 
or DNA genome, which is surrounded by a capsid composed of viral proteins, and 
sometimes a lipid envelope which encases the capsid1. For a virus to replicate, it must 
invade a host cell that is both susceptible and permissive to infection, as viruses usurp 
host cell machinery to mediate their replication and cause disease2. As a result, the host 
immune system develops specialized mechanisms to identify and destroy invading 
pathogens. A body’s first line of defense against invading pathogens are physical barriers 
such as epithelial tissues, stomach acid, and saliva3. To combat these defenses, pathogens 
have evolved to interact with cellular receptors and trick the host into internalizing them. 
Once inside, however, the pathogen must inhibit the activation of host intrinsic, innate, 
 
 
 
 
 
 
 
 
 Figure 1. Schematic of JCPyV genome: early and late genes. The non-coding control region (NCCR) contains the open reading frame (ORF) for the early genes 
(counter clockwise) and late genes (clockwise). The early genes include large T 
antigen (TAg) while the late gene include structural proteins such as viral protein 
1 (VP1). Used with permission from Ferenczy et al. 2012. Clinical Microbiology 
Reviews. 25, 471–506. 
 
 
2 
and adaptive immune responses to avoid destruction1. Due to the efficiency of the host 
immune system, some viruses are only capable of inducing disease once the immune 
system has been suppressed and are therefore defined as opportunistic viruses1.  
In 1971, a novel opportunistic virus was isolated from a patient suffering from 
progressive multifocal leukoencephalopathy (PML) and was named the human JC 
polyomavirus (JCPyV) after the patient’s initials4. The human JCPyV is non-enveloped 
with a capsid comprised of three viral proteins (VP1, VP2, VP3) and is ~45 nm in 
diameter5. The genome is circularized double stranded DNA containing one set of early 
and late-transcribed genes with a total length of 5130 base pairs (Figure 1)6. However, 
while the physical properties of JCPyV have been well examined, the infectious lifecycle 
of the virus remains poorly understood.  
JCPyV is thought to be transmitted via peroral transmission during early 
childhood due to poor sanitation practices, as it is shed in the urine and can be found in 
untreated wastewater7,8. Data based on recent serological studies suggest that at least 50-
80% of the human population is infected with JCPyV9. In healthy individuals, JCPyV 
establishes itself as an asymptomatic infection in the kidney and remains there as a 
lifelong, persistent infection controlled by the patient’s immune system8. When an 
individual becomes severely immunocompromised due to HIV infection, or through the 
use of immunosuppressive therapies for immune-mediated diseases like multiple 
sclerosis (MS), JCPyV can migrate from the kidney to the central nervous system 
(CNS)10. Within the CNS, JCPyV can infect the glial cells, astrocytes and 
oligodendrocytes, and result in their lytic destruction. These cells are critical for the 
production and maintenance of myelin within the brain and are necessary for healthy 
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brain function5. The destruction of the myelin-producing cells leads to severe 
demyelination, resulting in a disease called progressive multifocal leukoencephalopathy 
(PML)11.  
Due to gaps in our knowledge concerning viral-host cell interactions there are no 
effective therapies or treatments for either JCPyV infection or PML. As a result, the 
disease proves fatal to the majority of patients within 1 year of symptom onset4. To 
develop successful treatments, it is imperative to first understand the viral-host cell 
interactions that allows the virus to evade the immune system, persist within the host, and 
eventually become the etiological agent for PML. Further research investigating the 
signaling pathways that regulate these viral-host cell interactions in JCPyV infection will 
provide necessary insights into the infectious lifecycle and could serve as a platform for 
the development of effective treatments for populations at risk for PML. 
 
Progressive multifocal leukoencephalopathy 
While JCPyV was originally isolated in 1971, the first descriptions of PML were 
noted as early as 1930, and officially defined as a novel disease in 19584,14. The fatal 
disease was identified due to the destruction of the oligodendrocytes along with 
morphological changes in astrocytes and oligodendrocytes4. PML has an incidence rate 
(5-10%) in AIDS patients and is described as an AIDS defining illness15. Due to the 
increased use of immunosuppressive therapies for immune-mediated diseases like MS 
and Crohn’s disease, the incidence of PML has increased in these populations15. 
However, due to a lack of effective treatments for JCPyV infection or PML, the best 
options for patients are to treat the underlying immunosuppression by administering 
highly active antiretroviral therapy (HAART) for those infected with HIV or cease  
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immunomodulatory therapies for the preexisting disease like MS16. As a result, therapies 
are ranked in classes based upon their likelihood to increase a patient’s risk of developing 
PML4. The risk stratification is calculated based upon the risks and benefits to the patient 
by taking the therapy and ensures that patients who are at a high risk of developing this 
fatal disease are routinely examined4. 
Diagnosis of PML is accomplished through multiple methods. One common 
methodology is magnetic resonance imaging (MRI) to examine the brain for the loss of 
myelin, which appears as white plaque regions in the brain or CNS (Figure 2)7. In 
addition to identification of plaques through MRI, the preliminary diagnosis must also be 
confirmed through the presence of biomarkers, assays determining JCPyV load, and 
assays for JCPyV mRNA. A strong biomarker for PML in MS patients receiving the drug 
Natalizumab is CD62L, a selectin present on CD4+ T cells, that has been shown to be 
expressed at lower levels in patients that develop PML7. Patients can also be tested for 
the presence of JCPyV antibodies and genetic material in urine samples through PCR 
Figure 2.  Images of PML lesions and rapid disease progression. Magnetic 
resonance imaging scans utilizing 3D Flair techniques. White matter located in 
the brain marks the development of plaques over 2-months. Red arrow points to 
areas of PML lesions. Image credit: Biogen Idec. 
 
 
5 
techniques 7. Early detection of JCPyV infection for patients at risk of developing AIDS 
or beginning immunosuppressive therapies alerts physicians to closely monitor those 
patients for the development of PML. 
Upon disease onset, PML can develop in multiple regions of the brain and often 
spreads to multiple areas17. As a result, there is a wide range of symptoms that may be 
presented based on which region of the brain is being affected15. Classic symptoms can 
include vision impairment, loss of memory, and hemiparalysis15. It is also common for 
the afflicted individual to experience personality disorders upon symptom onset8. Once a 
patient begins showing clinical symptoms, PML proves fatal to the majority of patients 
within one year4. With no effective therapies or treatments available for either this 
disease or JCPyV infection, the only option patients receiving immunosuppressive 
therapies have is to cease immunosuppressive therapies. In doing so, however, patients 
face the progression of the underlying condition such as cancer, MS, or Crohn’s 
disease6,8,19. Additionally, ending immunosuppressive therapies also increases the 
patient’s risk of developing immune reconstruction inflammatory syndrome (IRIS)18. 
IRIS is caused by a rapid return of immune cells within the CNS and results in severe 
inflammatory responses and worsen the underlying disease condition18. Conversely, for 
individuals with HIV or AIDS initiation of HAART can delay onset of PML19. 
 
JCPyV infectious lifecycle 
Before JCPyV can disseminate through its host and cause PML, it must 
successfully establish a persistent infection. A successful JCPyV infection is dependent 
upon the virus encountering a permissive host cell, requiring the cell to have specific 
functionalities that support viral infection. Research has found that JCPyV initially 
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attaches to host cells via α2,6 linked sialic acids on lactoseries tetrasaccharide c (LSTc)12. 
This virus-host cell interaction is mediated by the JCPyV capsid protein, viral protein 1 
(VP1), which contains multiple binding sites for LSTc12. Interestingly, research suggests 
that in patients diagnosed with PML, VP1 has undergone mutations indicating that these 
mutations may be required for JCPyV spread from initial sites of infection to the CNS21. 
Following attachment to LSTc, JCPyV requires serotonin receptors to aid in viral 
infection23. 
 Serotonin 5-hydroxytryptamine (5-HT) receptors are seven transmembrane 
spanning G-protein-coupled receptors22. While there are multiple families of 5-HTRs, 
only the subtype 5-HT2Rs have been shown to be essential for JCPyV infection22,23. 
Currently, the mechanism by which 5-HT2Rs mediate JCPyV internalization is poorly 
understood. However, inhibition of the 5-HT2Rs inhibits JCPyV infection but has no 
effect on viral attachment to host cells 23,24. Interestingly, when 5-HT2Rs are expressed in 
human kidney cells, which naturally do not express the receptors but do express LSTc, 
the cells gain the ability to internalize JCPyV and can become infected22. Recent work 
from the Maginnis Laboratory suggests that JCPyV-mediated activation of 5-HT2Rs 
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results in viral 
internalization via 
clathrin-mediated 
endocytosis 
(Mayberry and 
Maginnis, 
unpublished data). 
This data 
corroborates the 
finding, which 
showed that inhibition of clathrin-mediated endocytosis reduced JCPyV internalization25. 
Once inside the cell, JCPyV traffics through the cytoplasm via endosomes and caveolin-1 
vesicles5. The virus is then deposited into the endoplasmic reticulum (ER) where the 
capsid undergoes a partial uncoating event prior to translocation to the nucleus for viral 
transcription and replication (Figure 3)26.  
 Upon arrival in the nucleus, the JCPyV genome is transcribed in a temporally-
regulated fashion in which the early genes are transcribed first (Figure 1)4. One of the 
early genes codes for the protein large tumor antigen (large T antigen (T Ag)), which is a 
major regulator of JCPyV replication4. Accumulation of T Ag within the cells promotes 
the transition from the production of early gene products, to late gene products, including 
VP16. Additionally, T Ag is capable of binding to host cell DNA to promote its transition 
from the G0 to S phase through the activation of host transcription factors4. While not all 
transcription factors required for JCPyV transcription have not been identified, some 
Figure 3. JCPyV internalization and infectivity pathway. JCPyV attaches to α2,6 LSTc 
receptor and enters cells by 5-hydroxytryptamine receptors (5-HT2)R through clathrin-mediated 
endocytosis. JCPyV traffics to early endosomes and cav-1 positive late endosomes, then to the 
ER where it undergoes uncoating, and enters the nucleus where transcription and replication 
occur. Used with permission from Maginnis et al. 2015. J. Neurovirol. 21, 601–13. 
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have been characterized that play an important role in JCPyV transcription including 
nuclear factor of activated T cells (NFAT)28. 
NFAT is regulated by the serine/threonine phosphatase calcineurin, which is 
activated by calcium (Ca2+) flux from the ER through the interaction of inositol 
triphosphate (IP3) with its receptor (IP3R)29. Upon activation, NFAT migrates from the 
cytoplasm to the nucleus and directly binds to promoter regions on the JCPyV genome to 
initiate transcription28. Inhibition of calcineurin utilizing the chemical inhibitor 
Cyclosporine a (CsA), results in a significant reduction in JCPyV infection28. Manley et 
al. demonstrated the importance of NFAT binding to JCPyV DNA to promote 
transcription of both the early and late viral genes. While these findings suggest the 
importance of NFAT regulation in JCPyV infection, the role of the IP3R signaling 
cascade in NFAT activation during JCPyV infection remains uncharacterized. 
 
 
 
 
 
 
 
 
 
 
Figure 4. 5-HT2R-activation of Ca2+/CaM signaling pathway. Activation of 5-HT2R leads to 
IP3 activation of the IP3R causing a release of Ca2+ from the ER, leading to the activation of 
calmodulin (CaM), which then binds to specific sites on the intracellular loops on the 5-HT2R, 
and/or calcineurin, which activates nuclear factor of activated T cells (NFAT), a transcription 
factor required for JCPyV infection. Inhibition of IP3R was accomplished utilizing the 
competitive inhibitor, 2-APB. 
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IP3R-mediated calcium signaling 
While the role of 5-HT2Rs in JCPyV entry and infection are not completely understood, it 
is known that ligand activation of 5-HT2Rs can activate multiple signaling cascades, 
which have been observed to regulate the JCPyV lifecycle20. The 5-HT2R recruits 
calmodulin (CaM), which activates phospholipase C (PLC) and hydrolyses PIP2 into IP3 
and diacylglycerol (DAG)29. Free IP3 binds to its receptor (IP3R) which is imbedded 
within the ER membrane and elicits a flux of calcium ions (Ca2+) into the cytoplasm. 
Increased cytoplasmic Ca2+ then becomes a universal regulator for a multitude of 
signaling cascades within a cell including activation of calcineurin, a seine/threonine 
phosphatase that regulate the activation of host transcription factors like NFAT and 
cellular proliferation (Figure 4)45. Additionally, the free Ca2+ may bind to CaM and result 
in binding to intracellular binding domains on the 5-HT2R, which stabilizes its expression 
on the exterior of the cell. 
Recent studies suggest that viruses have evolved to elicit the release of ER Ca2+ 
stores to drive various stages in their reproductive lifecycles. For example, the human 
immunodeficiency virus (HIV) is an enveloped, negative-stranded RNA virus that 
utilizes IP3R-mediated Ca2+ flux to localize Gag, viral structural proteins responsible for 
virion maturation, to the plasma membrane30. At the membrane, Gag mediates viral 
egress via endocytic sorting complex required for transport (ESCRT)31. Meanwhile, 
Dengue virus (DENV), an enveloped, positive-stranded RNA virus, induces Ca2+ flux 
from the ER to initiate store-operated Ca2+ entry (SOCE) to drive viral replication32. 
Furthermore, coxsackievirus B (CVB) is a nonenveloped, positive-sense RNA virus that 
utilizes IP3R-mediated Ca2+ flux to induce vacuolization of cells, which mediates viral 
 
 
10 
internalization and trafficking through the cell33. While these viruses have different 
physical structures, genomes, and egress strategies, they are all unified in their 
dependence on intracellular Ca2+ to drive infection. Based on the viral-induced Ca2+ flux 
pathways elicited by a wide-range of viruses and JCPyV activation of potential Ca2+-
driven signaling pathways through 5-HT2Rs22, MAPK26, and NFAT28, it is hypothesized 
that JCPyV also depends on IP3R-mediated Ca2+ release to drive the infectious viral 
lifecycle. 
 
Research goals 
The goal of this thesis research was to define the role of IP3R-mediated 
intracellular Ca2+ flux from the ER in regulating JCPyV infection. Studies using an ER-
specific Ca2+ reporter assay to track Ca2+ levels within the ER, suggest that JCPyV 
infection induces the release of ER Ca2+ stores at 2 h post infection. To determine 
whether Ca2+ flux is necessary for JCPyV infection, an IP3R chemical inhibitor was 
utilized and resulted in a dose-dependent-decrease in both viral VP1 and T Ag 
expression. JCPyV-induced Ca2+ flux within 0-3 h following viral infection, times that 
are consistent with viral attachment and entry. To elucidate the step in the virus lifecycle 
affected by the inhibition of Ca2+ flux, JCPyV attachment and internalization were 
examined. However, data revealed that treatment with the IP3R inhibitor had no effect on 
viral attachment or entry when compared to untreated cells. Together, these results 
suggest that JCPyV activates Ca2+ flux upon infection, and Ca2+ flux regulates JCPyV 
infection at a post-entry step in the virus lifecycle.  
 These data provide researchers with greater insight into the JCPyV infectious 
lifecycle and helps to increase our general understanding of the viral-host cell interactions 
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that impact human disease. Additionally, these experiments increase our understanding of 
the importance of Ca2+ signaling in viral infections within the field of virology. It is 
possible that this information may provide the insights necessary to identify novel targets 
for antivirals therapies for populations at risk of developing the fatal disease PML.  
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MATERIALS AND METHODS 
 
 
 
Cell culture maintenance 
Cell culture experiments were conducted utilizing Lab Gard II laminar flow hoods to 
maintain a sterile environment. SVG-A (human fetal glial cells transformed with SV40 T 
antigen) and human embryonic kidney cell lines that stably express 5-HT2AR 
(HEK293A-5-HT2AR) were generously provided from Dr. Walter Atwood’s laboratory 
(Brown University). Cells were maintained in T75 flasks and were grown in a humidified 
incubator at 37oC with 5% CO2. Cell lines were passaged upon visually reaching 90% 
confluency, as observed using a light microscope. SVG-A cells were cultured in 
Minimum Essential Medium (MEM) with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin (P/S) (Mediatech, Inc.), and 0.2% plasmocin (Invivogen). 
HEK293A-5-HT2AR cells were cultured with Dulbecco’s Modified Eagle Medium 
(DMEM) with the same concentrations of FBS, P/S, and plasmocin. For subculturing, 
cells were detached from flasks with 4 mL of 0.5% trypsin-EDTA (Gibco, Thermo 
Fischer Scientific) and incubated at 37oC for 5 mins. Following incubation, 9 mL of fresh 
media was added and transferred to a 15 mL conical tube. The cell suspension was 
centrifuged at 2,000 rpm for 5 min. Media was aspirated off the pelleted cells, which 
were then resuspended in 10 mL of fresh complete media and divided into a new flask for 
continued growth. The new T75 was incubated in a humidified incubator at 37oC and 5% 
CO2 until confluency was reached again.  
 
 
 
 
13 
Inhibition of Calcium Flux 
2-APB Treatment of SVG-A cells: Wells of a 24-well plate (Grenier Bio-One) were 
seeded with 2.4e5 cells/well in complete MEM and incubated in a humidified incubator 
at 37oC overnight (O/N). Once cells reached ~80% confluency by visual inspection, 
media was removed, and the 2-APB (Sigma-Aldrich) inhibitor, a competitive inhibitor of 
the IP3R, was added in complete MEM with a final volume of 1 mL/well (concentrations 
specified in Figure Legends). Cells were then incubated at 37oC for 2 h and then infected 
(described below).  
2-APB Treatment of HEK293A-5-HT2AR cells: Wells of a 24-well plate (Grenier Bio-
One) were seeded with 2.4e5 cells/well in complete MEM and incubated in a humidified 
incubator at 37oC O/N. Once cells reached ~80% confluency by visual inspection, media 
was removed, and the 2-APB inhibitor, a competitive inhibitor of the IP3R, was added in 
complete MEM with a final volume of 1 mL/well (concentrations specified in Figure 
Legends).  
Xestospongin C treatment of SVG-A cells: Wells of a 24-well plate (Grenier Bio-One) 
were seeded with 2.4e5 cells/well in complete MEM and incubated in a humidified 
incubator at 37oC O/N. Once cells reached ~80% confluency by visual inspection, media 
was removed, and the Xestospongin C inhibitor, an inhibitor of the IP3R, was added in 
complete MEM with a final volume of 1 mL/well (concentrations specified in Figure 
Legends). Cells were then incubated at 37oC for 30 min and then infected (described 
below).  
U73122 Treatment of SVG-A cells: Wells of a 24-well plate (Grenier Bio-One) were 
seeded with 2.4e5 cells/well in complete MEM and incubated in a humidified incubator 
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at 37oC O/N. Once cells reached ~80% confluency by visual inspection, media was 
removed, and the inhibitor U73122, which targets PLC, was added in complete MEM 
with a final volume of 1 mL/well (concentrations specified in Figure Legends). Cells 
were then incubated at 37oC for 24 h and then infected (described below).  
 
Cellular Proliferation Assay (MTS) 
To determine cytotoxic effects of chemical inhibitors, wells in a 96-well plate (Grenier 
Bio-One) were seeded with 1e4 cells/well in complete MEM and incubated at 37oC O/N. 
Once cells reached 80% confluency they were treated with the selected chemical, after 
which fresh media was added to a final volume of 100 µL per well. A volume of 20 µL of 
the MTS/PMS solution was then added, and cells were incubated at 37oC for 1 h. Post 
incubation, absorbance was recorded at 490 nm utilizing a BioTek Synergy2 plate reader. 
The average absorbances were calculated and compared to untreated cells at selected 
timepoints.  
 
JCPyV infection 
Cells that were pretreated with a chemical, control, or transfected with ER-GCaMP had 
media removed prior to infection. Cells were inoculated with JCPyV in fresh media 
(multiplicity of infections (MOIs) specified in Figure Legends). Viral infections were 
conducted in either complete MEM for chemical inhibitors, or phenol red-free complete 
MEM for ER-GCaMP transfected cells as specified. Cells were incubated with viral 
inoculums of 200 µL for 24-well plate and 40µL for a 96-well plate for 1 h incubation at 
37oC, then cells were fed with 1 mL of complete MEM for a 24-well plate (Grenier Bio-
One), or 60 µL for a 96-well plate (Grenier Bio-One). Cells that were being examined for 
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T Ag expression were incubated for 48 hpi while those being examined for VP1 
incubated for 72 hpi.  
 
Fluorescence Focus Assay (FFA) 
Following infection, cells were washed with 1 mL of 1XPBS then fixed in ice cold 
methanol. Fixed cells were then incubated at -20oC for at least 10 mins, washed three 
times for 10 mins with 1XPBS, and then permeabilized with PBS-0.5% TX100 during a 
15-min incubation.  
T Ag Staining: Following permeabilization, cells were blocked with 10% goat serum in 
1XPBS at RT for 45 min. Cells were then stained for presence of T Ag utilizing the 
primary PAB692 (1:50) and incubated at 37oC for 1 h (generously provided by the 
Tevethia lab, Penn State). Cells were washed with 1XPBS Tween (0.01%) three times at 
RT for 5 min. An anti-mouse Alexa Fluor-594 secondary antibody was used to detect the 
primary antibody, and cells were incubated at 37oC for 1 h. Finally, cells were washed 
with 1XPBS three times at RT for 5 min, then stored in 1XPBS Tween (0.01%) at 4oC 
prior to visualization and quantitation. 
VP1 Staining: Following permeabilization, cells were blocked with 10% goat serum at 
RT for 45 min. Cells were stained with a primary antibody PAB597 (1:10), a hybridoma 
supernatant, which produces a monoclonal antibody for JCPyV VP1 (provided by Ed 
Harlow), and incubated at 37oC for 1 h. Cells were washed with 1XPBS three times at RT 
for 5 min. An anti-mouse Alexa Fluor-488 secondary antibody (1:1000) (Thermo Fisher 
Scientific) was used to detect the primary antibody and incubated at 37oC for 1 h. Finally, 
cells were washed with 1XPBS three times at RT for 5 min and then stored in 1XPBS 
Tween (0.01%) at 4oC prior to visualization and quantitation. 
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Quantification: Cells were quantified for infectivity via epifluorescence microscopy by 
counting VP1+ cells in at least 5 visual fields per well in triplicate wells for 3 separate 
experiments. Expression of VP1 was observed under a 10x objective for a 24-well plate 
or 20x for a 96-well plate using a Nikon Eclipse Ti epifluorescence microscope. The total 
number of cells/visual field was quantified by staining cellular DNA with DAPI. DAPI 
positive cells were quantified using a binary created in the Nikon NIS-Elements Basic 
Research software (Version 4.5), which controls for equal diameter and circularity of 
DAPI+ nuclei based upon threshold fluorescence. The percentage of infected cells was 
calculated by dividing VP1+ cells by the total number of cells, and then normalizing 
values to the negative control (i.e. DMSO).  
 
Flow cytometry to measure JCPyV attachment 
SVG-A cells were cultured to 100% confluency in 6-well plates (Grenier Bio-One) and 
were treated with a DMSO control or 2-APB (300 µM) in complete MEM at 37oC for 2 
h. Cells were then removed from plates by washing with 1XPBS, then incubated with 
Cellstripper (Corning). SVG-A cells were pelleted at 376 x g at 4oC for 5 min and 
washed in 1XPBS. Cells were incubated with Alexa-488 fluorescently labeled JCPyV 
(JCPyV-488) in PBS (100 µL total volume) on ice for 2 h, agitating every 15 min. 
Following incubation, cells were washed and pelleted by centrifugation before being 
resuspended in a final volume of 500 µL of 1XPBS. Viral attachment (JCPyV-488) was 
examined utilizing a BD LSRII (BD Biosciences) with a 488 laser excitation line 
(Benton, Dickinson, and Company). Data were analyzed based upon 10,000 events using 
BD FACSDIVA (Benton, Dickinson, and Company) and FlowJo software (Tree Star, 
Inc.).  
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Trypan blue quenching assay 
SVG-A cells were plated to 100% confluency in 6-well plates (Grenier Bio-One) and 
pretreated with complete MEM containing either DMSO control or 2-APB (300 µM) at 
37oC for 2 h. Cells were then harvested by washing cells with 1XPBS, then incubated 
with Cellstripper (Corning) at 37oC for 5 min. Cells were centrifuged at 375 x g at 4oC 
for 5 min. The pellet was washed with 1XPBS, cells were pelleted again, and finally 
resuspended in phenol-free complete MEM and chilled at 4oC for 30 min. Cells were 
pelleted and resuspended with JCPyV-488 and incubated at 4oC for 1.5 h with agitation 
every 15 min. Post incubation, cells were resuspended with cold phenol-free complete 
MEM and were either fixed (attachment) or incubated at 37oC for 90 min (entry). At 0 or 
90 min post-incubation, cells were pelleted and resuspended in 4% PFA on ice for 10 
min. Cells were then washed and resuspended in 1XPBS or 1XPBS with Trypan blue 
(0.016%) in a final volume of 500 µL. Addition of Trypan blue to pre-treated JCPyV-488 
incubated cells quenches extracellular fluorescence. Therefore, only internalized JCPyV-
488 would remain detectable to the flow cytometer. Analysis for viral internalization was 
completed utilizing a BD LSRII equipped with a 488 laser line. Data were analyzed with 
BD FACSDIVA (Becton, Dickinson and Company) and FlowJo software (Tree Star, 
Inc.). Quenched (addition of Trypan blue) and protected samples (without Trypan blue) 
from DMSO- and 2-APB-treated cells were assessed by flow cytometry to determine 
viral attachment (incubation at 4oC only) and viral internalization (incubation at 37oC). 
Percent protected fluorescence of average FITC readings from quenched and protected 
samples were calculated by normalizing the mean fluorescence to cells alone. Three 
samples were examined for each condition, with each sample containing 10,000 events. 
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ER-GCaMP assay 
SVG-A cells were plated 5e3 cells/well in a 96-well black chimney, clear bottom plate 
(Grenier Bio-One) and incubated O/N at 37oC in complete MEM. Cells were then 
transfected with a plasmid containing the ER-GCaMP (provided by Drs. Tim Ryan and 
Julie Gosse) with Fugene6 (Promega) at a 0.2µg of DNA to 0.6µL of Fugene6 in a 
volume of 10 µL/well in phenol-free complete MEM. Cells were incubated at 37oC for 24 
h. The transfection treatment was then removed and replaced with complete MEM and 
incubated at 37oC for 48 h. Cells were then washed with a Tyrode’s buffer (pH 7.4) at 
37oC for 30 min. Cells treated with ionomycin or Tyrode’s buffer immediately before 
analysis every 45 sec for 1h (excitation 485/20 and emission 528/20) using a BioTek 
Synergy2 plate reader with Gen5 (version 5.0). Other cells were infected with JCPyV in 
Tyrode’s buffer at a MOI 0.5 FFU/cell and read every min for 3 h (excitation 485/20 and 
emission 528/20) using a BioTek Synergy2 plate reader with Gen5 (version 5.0). 
Readings were normalized to non-transfected or uninfected samples. 
 
Statistical Analysis 
Significance was determined utilizing the Microsoft Excel student’s paired t-test for at 
least triplicate samples. P values of < 0.05 were considered statistically significant.  
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RESULTS 
 
 
 
JCPyV directly induces Ca2+ flux from the ER 
Viral-host cell interactions that occur during viral attachment can induce Ca2+ flux 
from the ER to drive viral processes such as internalization, trafficking, replication, and 
egress by activating critical proteins31. The role of JCPyV-induced Ca2+ flux has 
remained unclear, yet recent studies have shown that ERK26 and NFAT28, which can also 
be regulated by IP3R-mediated Ca2+ release, are critical modulators of the JCPyV 
infectious lifecycle. To 
examine whether Ca2+ 
release occurs during 
JCPyV infection, an assay 
was developed to measure 
ER- specific Ca2+ release in 
SVG-A cells, a glial cell 
line optimized for studies of 
JCPyV infection. SVG-A cells were transfected with a plasmid containing the sequence 
for a molecular reporter of ER-specific Ca2+ signaling, ER-GCaMP. The molecule 
consists of an enhanced green fluorescent protein (GFP) synthetically attached to a CaM 
and M13 peptide, both of which act as Ca2+ binding domains, with an ER localization 
signal34. ER-GCaMP can only be excited and emit a signal when bound to Ca2+ ions 
within the ER. Emission is detected via plate reader and measured as relative 
Figure 5. ER-GCaMP is efficient for examining ER Ca2+ flux. SVG-A 
cells were transfected with an ER-GCaMP plasmid and incubated for 48 h. 
Cells were then treated with ionomycin. At selected time points, cells were 
analyzed for fluorescence intensity with a BioTek plate reader at 37oC every 
45 sec for 1 h to determine relative fluorescence units (RFUs). Data are 
representative of three experiments completed with three samples per 
treatment. ER-GCaMP is efficient for examining ER Ca2+ flux. 
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fluorescence units (RFUs). Therefore, changes in fluorescence measurements represent 
the relative levels of Ca2+ within the ER.  
To determine the sensitivity of the assay, transfected cells were examined for 
RFUs over the course of 1 h after adding ionomycin, a Ca2+ ionophore, or a CTL 
(DMSO) to the cells (Figure 5). Results showed a stable expression of RFUs in the CTL-
treated cells for the duration of the experiment while those treated with ionomycin 
showed a complete abolishment of relative fluorescence units immediately upon addition. 
These results therefore 
indicate that this assay is 
sensitive enough to detect 
variations in ER Ca2+ 
concentrations. Next, to 
determine the effect of 
JCPyV infection on Ca2+ 
flux, cells were mock 
infected (uninfected) or 
infected. Fluorescence was 
recorded for six samples 
every min for 3 h.  Mock-
infected cells retained a 
stable expression of RFUs 
throughout the duration of 
the experiment, while the 
Figure 7. 2-APB is efficient for inhibiting ER Ca2+ flux. SVG-A cells were 
transfected with an ER-GCaMP plasmid and incubated for 48 h. Cells were pretreated 
for 2-APB or CTL (DSMO) then treated with ionomycin. At selected time points, 
cells were analyzed for fluorescence intensity with a BioTek plate reader at 37oC 
every 45 sec for 1 h to determine relative fluorescence units (RFUs). ER-GCaMP is 
efficient for examining ER Ca2+ flux. 
Figure 6. JCPyV induces Ca2+ release from ER. SVG-A cells were transfected 
with an ER-GCaMP plasmid and incubated for 48 h. Cells were then infected with 
JCPyV (MOI = 0.5 FFU/cell). At selected time points, cells were analyzed for 
fluorescence intensity with a BioTek plate reader at 37oC every min for 3 h to 
determine relative fluorescence units (RFUs). Data are representative of three 
experiments completed with six samples per treatment. JCPyV infection induces 
ER Ca2+ release. 
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infected cells showed a complete abolishment at the time of infection (Figure 6). These 
results therefore suggest that JCPyV host-cell interactions are capable of eliciting an ER 
Ca2+ during infection, presumably as early at the viral attachment and entry5,12,22.  
 
IP3R-mediated Ca2+ flux is required for JCPyV infection 
While the ER-GCaMP studies revealed that JCPyV infection results in a release of ER 
Ca2+ stores at times consistent with viral attachment and entry, the role of Ca2+ flux on 
the JCPyV infectious cycle was unclear. Upon release from the ER, free Ca2+ ions act as 
ubiquitous secondary regulators for cellular functions35. Other viruses including HIV, 
influenza virus, and Dengue virus have been shown to induce Ca2+ flux from the ER to 
drive various steps in their infectious processes31,32. Therefore, to examine the effect of 
ER Ca2+ flux inhibition, cells were pretreated with various chemical inhibitors of the 
IP3R-mediated Ca2+ release signaling cascade to examine their effect on JCPyV infection. 
The competitive inhibitor of the IP3R, 2-APB36 (Figure 4), was tested for efficacy by 
determining whether it could inhibit Ca2+ flux from the ER utilizing the ER-GCaMP 
assay. Results showed that cells pretreated with 300 µM of 2-APB compared to CTL-
Figure 8. Pretreatment of cells with 2-APB inhibits nuclear expression of TAg. A) HEK-5-HT2AR cells were treated for 1 h or 
B) SVG-A cells were treated for 2 h with either a control (CTL) or 2-APB at 37oC and then infected with JCPyV at a MOI of 0.1 
FFU/cell. Cells were fixed, stained, and quantified for TAg expression by indirect immunofluorescence microscopy. Data represent 
the average percent infection for 3 visual fields for triplicate samples. Experiment was completed once in triplicate. Error bars 
represent the SD. *, P<0.03 and **, P<0.005, and ***P<0.005. Treatment with 2-APB reduces JCPyV infection. 
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treated cells retained higher relative fluorescence when treated with ionomycin (Figure 
7). These results therefore suggest that 2-APB is efficient at inhibiting Ca2+ flux from the 
ER.  
To further characterize whether Ca2+ flux is required for JCPyV infection, the 
kidney cell line HEK293A that stably express 5-HT2AR22 (HEK-5-HT2AR) and the glial 
cell line SVG-A cells were pretreated with 2-APB at indicated concentrations for 2 h, 
then infected with JCPyV. Infection was quantified using a fluorescence focus assay 
(FFA) of viral infectivity. Treatment of SVG-A cells with 2-APB lead to a dose-
dependent decrease in nuclear expression of both the early gene product T Ag (Figure 8) 
and late gene product VP1 (Figure 9). Additionally, SVG-A cells were pretreated with 
Xestospongin C, another competitive inhibitor of the IP3R, and then examined by FFA 
for VP1 expression (Figure 10). 
These results indicated a 
significant decrease of ~20% in 
viral infection, thereby 
corroborating with the 2-APB 
results (Figure 10). Given that 
PLC regulates the production of 
IP3 (Figure 4), SVG-A cells were 
pretreated with a PLC inhibitor 
(U73122) or DMSO control for 24 h prior to infection. Infectivity was scored using a 
FFA and cells were examined for VP1 expression. Cells treated with U73122 
demonstrated a ~20% decrease in JCPyV infection in comparison to DMSO control-
Figure 9. SVG-A cells treated with 2-APB inhibits nuclear expression 
of VP1. SVG-A cells were treated with either a control (CTL) or 2-APB, 
an inhibitor of ER Ca2+ release, then infected with JCPyV at an MOI of 0.1 
FFU/cell at 37oC for 1 h. Cells were fixed, stained, and quantified for VP1 
expression by indirect immunofluorescence microscopy. Data represent the 
average % infection for 3 visual fields for triplicate samples. Data are 
representative of three experiments completed in triplicate. Error bars 
represent the SD. *, P<0.05 and **, P<0.005. Treatment with 2-APB 
prevented JCPyV infection. 
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treated cells (Figure 11), suggesting the importance of the IP3R signaling pathway in 
JCPyV infection. To ensure chemical treatments were not inducing cellular cytotoxicity, 
SVG-A cells were subjected to treatments as described in the experimental procedures 
and a cellular proliferation assay was performed (Figure 12). The concentrations used in 
these studies did not exhibit cellular 
toxicity. Together, these data suggest 
that JCPyV utilizes IP3R-mediated 
Ca2+ flux from host cell ER stores to 
drive infection.  
 
JCPyV attachment is independent of 
IP3R-mediated Ca2+ flux 
Analysis of Ca2+ release from the ER 
upon JCPyV infection using the ER-
GCaMP assay revealed that Ca2+ 
release occurs immediately following 
infection (0-3 h), and which is a time 
consistent with viral attachment and 
entry5,12,20,22. To define whether 
JCPyV depends on IP3R-mediated 
Ca2+ release from the ER Ca2+ flux, 
viral attachment to cells treated with 2-
APB was measured by flow cytometry. 
SVG-A cells were pretreated with 300 
Figure 10. Pretreatment of cells Xestospongin C inhibits nuclear 
expression of VP1. SVG-A cells were pretreated with either a control 
(CTL) or Xestospongin C (Xesto C) for 1 h, then infected with JCPyV 
at an MOI of 0.1 FFU/cell at 37oC for 1 h. Media was added, and cells 
incubated for 72 h. Post incubation, cells were fixed, stained, and 
quantified for nuclear VP1 expression indirect immunofluorescence 
microscopy. The bars represent the average number of infected cells 
for 3 fields of view for triplicate samples. The error bars represent the 
SD. Xestospongin C resulted in ~30% decrease in JCPyV infection *, 
P<0.04. 
Figure 11. Pretreatment of cells with U73122 inhibits nuclear 
expression of VP1. SVG-A cells were pretreated with either a 
control (CTL) or U73122 at 37ᴼC for 24 h, then infected for 1 h. 
Media was added and cells incubated for 72 h. Post incubation, cells 
were fixed, stained, and quantified for nuclear VP1 expression 
indirect immunofluorescence microscopy. The bars represent the 
average number of infected cells for 3 fields of view for triplicate 
samples. Experiment was completed three times in triplicate. The 
error bars represent the SD. U73122 resulted in a dose dependent 
decrease in JCPyV infection. *, P<0.005. 
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µM of 2-APB, or CTL (DMSO) at 37oC for 2 h. Cells were detached from plates, 
suspended, and incubated at 4oC on ice to induce rigidity in the cell membranes to limit 
JCPyV internalization. Treated cells were then incubated with an Alexa-488-labeled 
JCPyV (JCPyV-488) at 4oC on ice to mediate viral attachment for 90 min37. Viral 
attachment was measured by flow cytometry analysis of the mean fluorescence (JCPyV-
488) of 10,000 events per treatment (Figure 13). Results showed no significant change in 
the mean fluorescence between the 2-APB- or control-treated cells, and that fluorescence 
is correlated to the presence of JCPyV-488 attachment to SVG-As. These results suggest 
that inhibition of Ca2+ release from the ER with 2-APB treatment does not affect JCPyV 
binding to host cells. Therefore, it is likely that Ca2+ flux regulates a post-attachment step 
in the JCPyV lifecycle.  
Figure 12. Chemical inhibitors do not affect cellular proliferation. SVGA cells were treated with either a control (CTL) 
A) 2-APB for 2 h, B) U73122 for 24 h, or C) Xestospongin C for 1h at 37ᴼC. Post incubation, treatment was removed and 
replaced with an equivalent volume of media, and cells were incubated at 37ᴼC for a total of 72 h. MTS was then added to 
each well and incubated for 1h at 37ᴼC. Absorbance was measured at 490 nm. Data represent the average absorbance for 
triplicate samples. Data are representative of three experiments completed in triplicate. Error bars represent SD. Pretreating 
SVGA cells with 2-APB, U73122, or Xestospongin C does not induce cytotoxicity. 
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JCPyV internalization is independent of IP3R-mediated Ca2+ flux 
Recent data has demonstrated the importance of ER Ca2+ signaling in driving viral 
internalization in the infectious viral lifecycles, including the viral entry step the herpes 
simplex virus38. Further, ER Ca2+ flux occurs very early during JCPyV infection (Figure 
6), suggesting that Ca2+ flux may regulate viral internalization. To determine whether 
Ca2+ flux regulated JCPyV entry, SVG-A cells were pretreated with 300 µM of 2-APB or 
a CTL (DMSO), and cells were 
suspended in 1XPBS and incubated at 
4oC on ice for 30 mins to induce 
membrane rigidity. Cells were then 
incubated with JCPyV-488 in 1XPBS at 
either at 4oC on ice (attachment) and 
fixed or shifted to 37oC (entry) for 90 min 
(Figure 14). Post incubation, cells were 
washed and treated with or without 
Trypan blue, which quenches the 
extracellular Alexa-488 fluorescence 
while internalized fluorescent molecules 
are protected from quenching37. 
Triplicate samples were analyzed by flow cytometry (10,000 events for each sample). 
Data was analyzed to determine the amount of virus that had been internalized (% 
protected fluorescence), which revealed no change in mean fluorescence between the 
control- or 2-APB- pretreated SVG-A cells (Figure 14). These results suggest that IP3R-
Figure 13. 2-APB does not affect JCPyV attachment to 
SVG-A cells. To examine viral binding, SVG-A cells were 
pretreated for 2 h with 2-APB, DMSO (CTL), or PBS (Cells 
alone) then incubated with fluorescently-labeled JCPyV 
(JCPyV-488) on ice for 1 h. Cells were analyzed using flow 
cytometry to detect JCPyV-488. The mean fluorescence 
intensity was determined for 10,000 events measured. 
Pretreatment of cells with 2-APB does not impact JCPyV 
attachment. 
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mediated Ca2+ flux has no effect on JCPyV internalization. Therefore, it is hypothesized 
that Ca2+ flux, which is required for JCPyV infection, affects a post-attachment and post-
internalization step in the JCPyV replication cycle.  
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DISCUSSION 
 
 
 
Due the diverse role of Ca2+ in cellular signaling, it is defined as a ubiquitous 
secondary signaling regulator in healthy cells and during times of human disease35. 
Research has shown that specific viral-host cell interactions can elicit Ca2+ release from 
the ER to promote viral infection27,31,36,38. Interestingly, Ca2+ flux can be initiated upon 
ligand binding and activation of G-protein coupled receptors (GPCRs), which include the 
5-HT2Rs that are required for JCPyV entry and infection22,23. Subsequent signaling 
cascades are initiated and result in the activation of the IP3R, a Ca2+ ion channel located 
within the membrane of the ER39. This free cytosolic Ca2+ is responsible for activating 
various host transcription factors, proteins involved with endocytosis in addition to 
dictating cellular proliferation and death, and membrane budding40. 
This research has shown that JCPyV infection results in the release of ER Ca2+ at 
times consistent with viral attachment and entry through a novel application of the ER-
GCaMP assay (Figure 6)20,34. Additionally, examination of both early and late viral gene 
products revealed a dose-dependent decrease in viral protein expression in cells 
pretreated with either an IP3R or PLC inhibitor. These results suggest that the Ca2+ flux 
regulates a step in the JCPyV infectious cycle prior to transcription (Figure 8-10). 
However, there was no change in either viral attachment or entry in the presence of the 2-
APB inhibitor (Figures 13 and 14), suggesting that Ca2+ flux has no effect on JCPyV 
attachment or entry. Therefore, JCPyV-induced Ca2+ flux is hypothesized to regulate a 
process post viral entry and prior to transcription and has the potential to regulate 
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multiple steps in the JCPyV infectious cycle, such as trafficking, partial uncoating of the 
viral capsid, and activation of host transcription factors.  
Following internalization, JCPyV is trafficked through the cytoplasm within the 
endocytic compartment via early endosomes and caveolin-1+ vesicles25,41. Early 
endosome formation and function are 
closely regulated by Ras-associated 
binding protein 5 (Rab5)42. Rab5 is 
activated via GTPases that are 
regulated by GPCRs43. Rab5 recruits 
Rab effector proteins, which are 
responsible for endosomal fusion and 
trafficking42. As JCPyV has been 
shown to require a specific family of 
GPCRs, 5-HT2Rs, it is possible that 
their activation not only mediates 
viral internalization, but also induces ER Ca2+ flux to activate Rab5 for early endosomal 
trafficking. Early endosomal trafficking is a necessary step in the JCPyV lifecycle, which 
results in delivery of the virus to the ER where the capsid undergoes a partial uncoating4. 
This uncoating process is required for viral deposition into the cytosol and eventual 
translocation to the nucleus where the viral genome is released for transcription and viral 
replication4. It is therefore possible that modulation of the ER Ca2+ release inhibits viral 
trafficking and therefore reduces viral transcription. This would therefore be consistent 
Figure 14. 2-APB does not affect JCPyV entry in SVG-A cells. 
SVG-A cells were pretreated with 2-APB at 37oC for 2 h then 
incubated with fluorescently-labeled JCPyV on ice for 1 h for viral 
attachment. Cells were treated with or without trypan blue to 
quench extracellular fluorescence or incubated at 37oC for 90 min 
to mediate viral entry and subsequently treated with trypan blue. 
Internalized virions were protected within the cell and capable of 
detection using flow cytometry. Pretreatment of cells with 2-APB 
does not affect JCPyV internalization. 
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with results showing inhibition of Ca2+ flux results in decreased expression of both early 
and late viral gene products (Figure 8 and 9).  
Additionally, it is also possible that IP3R-mediated ER Ca2+ flux, thereby altering 
the ER’s internal environment, is affecting JCPyV capsid uncoating. Research has shown 
that inhibiting the release of cellular Ca2+ stores negatively affects the viral uncoating 
processes within the ER37. Research by Nelson et al. suggests that release of ER Ca2+ 
activates ER-localized enzymes responsible for mediating JCPyV uncoating37. Therefore, 
it is possible that JCPyV induces IP3R-mediated ER Ca2+ to regulate the ERAD pathway 
and subsequent capsid uncoating within the ER. This Ca2+ release would occur early in 
the JCPyV lifecycle, which is demonstrated through the ER-GCaMP assay examining ER 
Ca2+ in JCPyV infected cells (Figure 6). Failure of JCPyV to partially uncoat in the ER 
would inhibit the delivery of the viral genome into the nucleus, and therefore inhibit viral 
transcription. This is also consistent with the reduced expression of both early and late 
viral gene products when IP3R-mediated Ca2+ release was inhibited with 2-APB (Figure 
7).  
Furthermore, ER Ca2+ flux could affect the activation of the protein kinase C 
(PKC) signaling pathway, which occurs post-entry and prior to viral transcription in the 
JCPyV lifecycle26. Cytosolic Ca2+ is capable of activating PKC, a kinase, which regulates 
the MAPK signaling pathway44. PKC initiates the MAPK cascade by phosphorylating 
Ras, which leads to the subsequent activation of Raf, MEK, and ERK44. Interestingly, the 
ER-GCaMP results revealed that Ca2+ flux occurs immediately upon viral infection. 
These results interestingly coincide with recent studies showing that the activation of 
ERK through phosphorylation occurs shortly after JCPyV infection26.  Interestingly, the 
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activation of ERK has also been linked to the regulation of NFAT, a molecule known to 
be a critical regulator in JCPyV transcription and infection28,45. Therefore, it is possible 
that JCPyV induced Ca2+ release is promoting viral gene transcription by regulating 
necessary transcription factors through the activation of PKC.  
As Ca2+ is defined as a universal secondary regulator, the ion itself would not be a 
viable target for either JCPyV infection or PML35. Inhibition of the ion could result in 
host cell death and thus lead to serious medical complications. One example is the 
importance of Ca2+ release in neuron activity. In this pathway glutamate activates a 
GPCR to create IP3, which then binds to its receptor and induces a Ca2+ flux. This 
calcium flux results in Ca2+-initiated Ca2+ release (CICR) and creates action potential 
within the pacemaker neurons of a human brain29. Similarly, Ca2+ signaling is also a 
critical regulator for muscle contraction, including muscles involved in regulating the 
heart29. Thus, it would be better to utilize our understanding of the role Ca2+ signaling 
pathway in regulating JCPyV infection to identify novel targets for JCPyV therapies. As 
the data has shown that ER Ca2+ release fails to inhibit viral attachment or internalization, 
yet it does have an effect on viral replication, and future research could help identify 
possible therapeutic targets such as transcription factors (NFAT) or activation of kinases 
such as ERK that regulate phosphorylation of transcription factors. Currently, there are 
inhibitors for the phosphatase calcineurin (Cyclosporin A) which regulates NFAT, and 
U0126 which inhibits ERK activation26,28. These could serve as the basis for developing 
novel therapies. 
Additionally, this research has described a new molecular assay sensitive enough 
to detect changes in Ca2+ concentrations within a selected organelle during viral 
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infection. This assay, along with the Ca2+ inhibition assays, has provided deeper insight 
how viral-host cell interactions regulate JCPyV infection and specifically how IP3R-
mediated Ca2+ release regulates viral infection and pathogenesis. These findings can be 
applied broadly to the field of virology to increase our understanding of viral-induced 
signaling pathways that drive viral infection, influence viral pathogenesis, and ultimately 
influence human disease development.  
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